Meyer et al., Leukocyte count and new-onset diabetes mellitus in PWH
Leukocyte count and new-onset diabetes mellitus in people with HIV: A longitudinal study Meyer SC and colleagues investigated the association of leukocyte count and new-onset diabetes mellitus in the SHCS using a matched case-control study design with incidence density sampling. The study benefits from an extensive observation period of more than 23 years and detailed […]
Labarile et al., Polygenic risk scores for type 2 diabetes in the Swiss HIV Cohort Study
Understanding Genetic Risk for Diabetes in People Living with HIV: What It Means for the Community Type 2 diabetes (T2D) is one of the most common health problems affecting people living with HIV (PWH). Research has shown that PWH are more likely to develop T2D than those without HIV, and scientists have been trying to […]
Han et al., Cancer risk with poor immune recovery
Risk of cancer in people with HIV experiencing different levels of immune recovery despite sustained viral suppression  Cancer remains a major cause of morbidity and mortality among people with HIV. Whether incomplete CD4 recovery continues to influence cancer risk once viral suppression is maintained has been unclear. In this large international study, Han et al. […]
Aghlmandi et al., Trends in costs for HIV care during an HCV program
Trends in costs for HIV care during the HCV early treatment and elimination program: A data linkage study of claims and Swiss HIV Cohort Study data In a study recently published in Open Forum Infectious Diseases, Aghlmandi et al investigated the impact of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) on […]
Elvastam et al., Viremia does not independently predict cardiovascular disease in PWHIV
Viremia Does Not Independently Predict Cardiovascular Disease in People With HIV: A RESPOND Cohort Study People living with HIV (PWHIV) have a higher risk of developing cardiovascular disease (CVD) compared with the general population. One possible reason is HIV viremia. The aim of this study was to examine whether HIV viremia is independently associated with […]
Foulkes et al., Variability in bnAb efficacy due to HIV-1 Env plasticity
Assessing bnAb potency in the context of HIV-1 envelope conformational plasticity Scientists around the world are working to develop vaccines and treatments for HIV that rely on special antibodies called broadly neutralizing antibodies (bnAbs). These antibodies can target and block a wide variety of HIV strains. However, one of the big challenges in HIV research […]
Ingle et al., Harmonization of alcohol use data and mortality across a multi-national HIV cohort collaboration
Harmonization of alcohol use data and mortality across a multi-national HIV cohort collaboration So far, no standardized approach to assess alcohol use has been established universally, which complicates comparability between different settings and studies. In some settings, including the SHCS since 2013, the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaire is used, whereas other settings […]
Sconza et al., Outcomes after prenatal exposure to raltegravir-containing antriretroviral therapy
Outcomes after prenatal exposure to raltegravir-containing antiretroviral therapy Integrase inhibitors such as raltegravir are increasingly used during pregnancy due to their rapid viral suppression and good tolerability, but data on their safety during early pregnancy remain limited. Sconza et al and the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) analyzed 1,499 pregnancies with raltegravir […]
Tusch et al., Mortality using raltegravir versus other integrase stand-transfer inhibitors in PWH in Europe and Australia
Mortality using raltegravir versus other integrase strand-transfer inhibitors in people with HIV in Europe and Australia: a prospective multicentre study Raltegravir (RAL) was the first integrase inhibitor and remains an antiretroviral treatment option for people with HIV in many places. However, some earlier studies raised concerns about higher mortality among people starting RAL compared with […]
Kraef et al., Incident TB in PWH across Europe from 2012 to 2022
Incident tuberculosis in people with HIV across Europe from 2012 to 2022: incidence rates, risk factors and regional differences in a multicentre cohort study The aim of this study is to describe the incidence of TB, evaluate the impact of modifiable risk factors, in particular being off antiretroviral therapy and smoking and to calculate their […]